Patents by Inventor Timothy P. REILLY

Timothy P. REILLY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CBL-B INHIBITOR, COMPOSITIONS COMPRISING A CBL-B INHIBITOR IN A METHOD OF TREATING A DISEASE ASSOCIATED WITH CELL PROLIFERATION
    Publication number: 20250161278
    Abstract: The present disclosure relates to treatment of a subject in need thereof of comprising administering a therapeutically effective amount of a CBL-B inhibitor.
    Type: Application
    Filed: January 10, 2025
    Publication date: May 22, 2025
    Inventors: Fang WANG, Yilin QI, Timothy P. REILLY
  • TREATMENT OF CELL PROLIFERATION-ASSOCIATED CONDITIONS USING A COMBINATION OF A CLB-B INHIBITOR AND AN ADDITIONAL THERAPEUTIC AGENT
    Publication number: 20250152569
    Abstract: The present disclosure relates to treatment of a subject in need thereof of comprising administering a therapeutically effective amount of a CBL-B inhibitor and a therapeutically effective amount of an additional therapeutic agent.
    Type: Application
    Filed: January 10, 2025
    Publication date: May 15, 2025
    Inventors: Fang WANG, Yilin QI, Timothy P. REILLY
  • MODIFIED FGF-21 POLYPEPTIDES AND USES THEREOF
    Publication number: 20170189486
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Inventors: Paul E. MORIN, Daniel COHEN, Ranjan MUKHERJEE, Timothy P. REILLY, Rose C. CHRISTIAN, Dasa LIPOVSEK, Ray CAMPHAUSEN, John KRUPINSKI
  • Modified FGF-21 Polypeptides Comprising an Internal Deletion and Uses Thereof
    Publication number: 20170029479
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: July 20, 2016
    Publication date: February 2, 2017
    Inventors: Paul E. MORIN, Daniel COHEN, Ranjan MUKHERJEE, Timothy P. REILLY, Rose C. CHRISTIAN, Dasa LIPOVSEK, Ray CAMPHAUSEN, John KRUPINSKI
  • Modified FGF-21 Polypeptides and Uses Thereof
    Publication number: 20160115213
    Abstract: Modified FGF-21 polypeptides and uses thereof are provided, for example, for the treatment of diseases associated with fibrosis. Modified FGF-21 polypeptides are disclosed that contain an internal deletion and optionally replacement peptide, optionally modified with at least one non-naturally-encoded amino acid, and/or optionally fused to a fusion partner.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 28, 2016
    Inventors: Paul E. MORIN, Daniel COHEN, Ranjan MUKHERJEE, Timothy P. REILLY, Rose C. CHRISTIAN, Dasa LIPOVSEK, Ray CAMPHAUSEN, John KRUPINSKI